Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease

Table 4 Drug-related adverse events in the terlipressin treatment group and the conventional treatment group

	Terlipressin treatment group (n = 32)	P-value
Nausea or vomiting	1
Angina pectoris	0
Arrhythmia	0
Elevated blood pressure	0
Persistent diarrhea	0
others	0
total	1(3.3%)	0.252

During the continuous intravenous infusion of low-dose terlipressin, vomiting was present in one of the patients on the second day of treatment, lasting for more than 2 days, on top of other factors, it was considered a side effect of terlipressin, and the medication was discontinued. No serious adverse events were found in other patients

ISSN: 1471-230X